Description: This product is discontinued due to commercial reason. Tecovirimat (formerly known as ST-246; SIGA-246; trade name: TPOXX), a p37 envelope protein inhibitor, is a small synthetic antiviral compound being developed to treat pathogenic orthopoxvirus infections of humans like smallbox. On 7/13/2018, FDA approved Tecovirimat for the treatment of smallbox infection. Tecovirimat was discovered as part of an HTS/high throughput screen program designed to identify inhibitors of vaccinia virus-induced cytopathic effects. The antiviral activity is specific for orthopoxviruses and the compound does not inhibit the replication of other RNA- and DNA-containing viruses or inhibit cell proliferation at concentrations of compound that are antiviral. Tecovirimat is an antiviral with activity against orthopoxviruses such as smallpox and is currently undergoing clinical trials. It works by blocking cellular transmission of the virus, thus preventing the disease.